GSK Bio
NEWS
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
As the sun rose on a new year, approximately 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
The U.S. Food and Drug Administration (FDA) had several approvals this week. Read on to see what the regulatory agency gave the go-ahead to.
JOBS
IN THE PRESS